Cohance Lifesciences has entered into an agreements with Chromo Laboratories India for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit (CR Bio), for a consideration of Rs 16 crore. The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations. The said transaction is expected to be completed in Q2 FY26, subject to satisfaction of customary closing conditions under the said agreements.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1282.15 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2249.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: